Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2024-03-08 | 2024-04-19 | 221678 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-10-27 | 2024-01-05 | 208370 |
| APO-DAPAGLIFLOZIN-METFORMIN | 850MG 5MG | TABLET | Resolved | 2024-12-05 | 2024-12-13 | 244918 |
| APO-DAPAGLIFLOZIN-METFORMIN | 1000MG 5MG | TABLET | Resolved | 2024-06-20 | 2024-08-02 | 231020 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-01 | 2024-07-05 | 212368 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-10-01 | 2022-01-24 | 146503 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-14 | 2022-02-03 | 152758 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-10-11 | 213547 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2020-06-04 | 2020-06-26 | 116530 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2024-06-06 | 2024-10-07 | 229752 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2021-01-08 | 2021-03-17 | 131145 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2020-10-14 | 2020-11-02 | 126277 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-02-19 | 2021-03-04 | 134430 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2022-12-05 | 2023-03-16 | 177126 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2024-04-19 | 2024-06-21 | 225776 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-03-25 | 132715 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2024-09-12 | 2024-09-20 | 237354 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2025-08-14 | 2025-11-21 | 265269 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |